GPR3 Antibody
| Code | Size | Price |
|---|
| PSI-5175-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-5175-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
GPR3 Antibody: ACCA, ACCA, G-protein coupled receptor 3, ACCA orphan receptor
Application Note:
GPR3 antibody can be used for detection of GPR3 by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in mouse samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in mouse samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
GPR3 Antibody: GPR3, also known as ACCA, is a G-protein coupled receptor that constitutively activates adenylate cyclase and is highly expressed in the central nervous system. Overexpression of GPR3 stimulates the production of amyloid-beta peptide (Abeta), the deposition of which is one of the pathological hallmarks of Alzheimer 's disease (AD), while the ablation of GPR3 prevented the accumulation of Abeta in vitro and in an AD mouse model. This is of particular interest because of the proximity of a reported candidate Alzheimer 's disease (AD) locus, suggesting that GPR3 may be a potential therapeutic target for the treatment of AD. GPR3 has also been shown to block the proliferation of cerebellar granule cell precursors (GCP) during postnatal development by inhibiting the Shh-induced proliferation of GCP, indicating that GPR3 activation may represent one of the signals that triggers the postnatal cell cycle exit and terminal differentiation of GPCs.
Background References:
- Marchesse A, Docherty JM, Nguyen T, et al. Cloning of human genes encoding novel G protein-coupled receptors. Genomics1994; 23:609-18.
- Eggerickx D, Denef JF, Labbe O, et al. Molecular cloning of an orphan G-protein-coupled receptor that constitutively activates adenylate cyclase. Biochem. J.1995; 309:837-43.
- Thathiah A, Spittaels K, Hoffmann M, et al. The orphan G protein-coupled receptor 3 modulates amyloid-beta peptide generation in neurons. Science2009; 323:946-951.
- Blacker D, Bertram L, Saunder AJ, et al. Results of a high-resolution genome screen of 437 Alzheimer's disease families. Hum. Mol. Genet.2003; 12:23-32.
Buffer:
GPR3 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
GPR3 antibody was raised against a 13 amino acid synthetic peptide from near the carboxy terminus of human GPR3.
The immunogen is located within the last 50 amino acids of GPR3.
The immunogen is located within the last 50 amino acids of GPR3.
NCBI Gene ID #:
2827
NCBI Official Name:
G protein-coupled receptor 3
NCBI Official Symbol:
GPR3
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 36 kDa
Observed: 36 kDa
Observed: 36 kDa
Protein Accession #:
P46089
Protein GI Number:
1170006
Purification:
GPR3 Antibody is affinity chromatography purified via peptide column.
Research Area:
Neuroscience
Swissprot #:
P46089
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | GPR3 Peptide | PSI-5175P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|